Ascendis Pharma (ASND) has released an update.
Ascendis Pharma has announced its Q2 2024 financial results, highlighting a 134% year-over-year volume growth in SKYTROFA sales, tempered by a negative adjustment for market access costs. The FDA approval of YORVIPATH as the first treatment for hypoparathyroidism in adults and the anticipation of pivotal trial results for TransCon CNP mark significant milestones for the company’s growth. Despite revenue adjustments, Ascendis revises its SKYTROFA revenue outlook to €220 – €240 million for the year, signaling confidence in continued growth.
For further insights into ASND stock, check out TipRanks’ Stock Analysis page.